Larazotide

Mechanism of Action

Larazotide acetate works primarily by protecting and restoring intestinal barrier function through multiple cellular mechanisms. Based on available evidence, the compound appears to target tight junction integrity and inflammatory pathways in the intestinal mucosa.

Intestinal Barrier Protection

Research demonstrates that larazotide acetate protects the intestinal mucosal barrier from anoxia/reoxygenation injury through various cellular mechanisms (PMID: 41153766). This suggests the compound may work by:

• Preserving tight junction protein function during cellular stress
• Maintaining epithelial cell integrity under adverse conditions
• Supporting cellular recovery mechanisms following injury

Anti-inflammatory Effects

The compound shows anti-inflammatory properties in multiple contexts. In a mouse model of non-alcoholic fatty liver disease (NAFLD), larazotide acetate demonstrated preventive effects (PMID: 40562584). Additionally, clinical observations suggest it may aid in viral spike antigen clearance and recovery in children with post-COVID multisystem inflammatory syndrome (PMID: 40737433).

Sustained Release Formulations

When formulated in hyaluronic acid hydrogels for sustained release, larazotide maintains antibacterial properties and shows effectiveness in treating colitis (PMID: 40915363), indicating the compound retains bioactivity across different delivery systems.

Clinical Development Context

Clinical trials have investigated larazotide acetate primarily for celiac disease symptom relief (NCT03569007, NCT00362856) and more recently for long COVID treatment (NCT05747534). However, the Phase 3 celiac disease trial was terminated, and specific molecular targets remain incompletely characterized in the available literature.

Note: The evidence base for larazotide's precise molecular mechanisms is limited. While studies demonstrate protective effects on intestinal barriers and anti-inflammatory properties, detailed mechanistic pathways require further investigation. This information is for educational purposes only and should not replace professional medical advice.

Larazotide acetate (also known as AT-1001) is primarily being investigated as a therapeutic agent for conditions involving intestinal barrier dysfunction. Based on available clinical trial and research evidence, its main applications include:

Celiac Disease

The most established clinical application for larazotide is in celiac disease management. A completed Phase 2 safety and tolerability study (NCT00362856) evaluated larazotide acetate in celiac disease patients. However, a subsequent Phase 3 efficacy and safety trial (NCT03569007) aimed at evaluating larazotide for relief of celiac disease symptoms was terminated, suggesting challenges in demonstrating clinical efficacy at this stage of development.

Recent research indicates larazotide may help protect the intestinal mucosal barrier, which is compromised in celiac disease. The compound appears to work through various cellular mechanisms to maintain barrier function, though clinical translation of these effects remains under investigation.

Long COVID

A Phase 2 trial (NCT05747534) is currently investigating larazotide acetate (AT1001) for treating Long COVID, though this study is no longer actively recruiting participants. The rationale for this application likely relates to the compound's potential effects on barrier function and inflammation.

Post-COVID Multisystem Inflammatory Syndrome

Emerging research has explored larazotide's use in children with post-COVID multisystem inflammatory syndrome, with one study reporting effects on viral spike antigen clearance and recovery, though more evidence is needed to establish clinical efficacy.

Other Investigational Areas

Research has examined larazotide's potential in several other conditions:

• Colitis: Studies have investigated sustained-release formulations for colitis treatment
• Non-alcoholic fatty liver disease (NAFLD): Preventive effects have been observed in mouse models
• Ischemia-reperfusion injury: Research suggests protective effects against anoxia/reoxygenation injury

Current Clinical Status

The clinical development of larazotide appears mixed, with the termination of the Phase 3 celiac disease trial representing a significant setback. However, ongoing investigation in Long COVID and other barrier-related conditions suggests continued interest in the compound's therapeutic potential.

Disclaimer: This information is for educational purposes only and should not be considered personalized medical advice. Patients should consult healthcare providers regarding treatment options for their specific conditions.

The safety evidence for larazotide is limited and mixed, with most data coming from preclinical studies and a small number of clinical trials, some of which were terminated.

Known Side Effects

Evidence is thin on specific side effects in humans. The available clinical trials include:

• One Phase 2 safety and tolerability study in celiac disease patients (NCT00362856) - completed, but specific safety results not provided in the evidence
• One Phase 3 efficacy and safety study (NCT03569007) that was terminated, raising potential safety concerns
• An ongoing Phase 2 trial for long COVID treatment (NCT05747534)

Without access to the detailed results from these trials, the specific side effect profile in humans remains unclear.

Contraindications

No specific contraindications are established based on the available evidence. The safety data is insufficient to determine absolute contraindications.

Drug Interactions

No drug interactions are documented in the provided evidence. This represents a significant knowledge gap requiring further investigation.

Special Populations

The evidence includes some pediatric data, as one study examined larazotide treatment in "children with post-COVID multisystem inflammatory syndrome." However, safety data for special populations is extremely limited, including:

• Pregnant or breastfeeding women
• Elderly patients
• Patients with kidney or liver impairment
• Children (beyond the single post-COVID study)

Important Safety Considerations

The termination of a Phase 3 clinical trial (NCT03569007) for celiac disease is concerning and suggests potential safety or efficacy issues, though the specific reasons are not provided in the evidence.

Most safety data comes from animal studies examining conditions like eosinophilic enteritis, colitis, and fatty liver disease, which cannot be directly extrapolated to human safety.

Disclaimer

This information is for educational purposes only and should not replace professional medical advice. The safety profile of larazotide remains poorly characterized in humans. Patients considering this treatment should consult with their healthcare provider to discuss potential risks and benefits based on their individual medical situation.

The evidence for larazotide safety in humans is notably thin, and significant gaps exist in our understanding of its safety profile.

Research Papers and Clinical Trials

Larazotide acetate (also known as AT-1001) has been studied across multiple conditions, with most research focusing on intestinal barrier function and inflammatory conditions.

Celiac Disease Research

The primary therapeutic target for larazotide has been celiac disease, where it aims to protect intestinal barrier function. A Phase 2 safety and tolerability study in celiac disease patients was completed (NCT00362856), though a subsequent Phase 3 efficacy and safety trial was terminated (NCT03569007). Recent narrative reviews have examined larazotide alongside other interventions for celiac disease management, though specific efficacy data from these reviews is not detailed in the available evidence.

Intestinal Barrier Protection

Laboratory studies have demonstrated larazotide's protective effects on intestinal barriers. One 2025 study published in Biomedicines showed that larazotide acetate protects intestinal mucosal barriers from anoxia/reoxygenation injury through multiple cellular mechanisms, though the specific study design and sample sizes are not provided in the available evidence.

Emerging Applications

Recent research has explored larazotide in several new therapeutic areas:

• Long COVID: A Phase 2 trial is currently active but not recruiting participants to evaluate AT1001 for long COVID treatment (NCT05747534)
• Pediatric inflammatory conditions: A 2025 study in Science Translational Medicine reported that larazotide treatment helped clear viral spike antigens and improved recovery in children with post-COVID multisystem inflammatory syndrome
• Liver disease: Research published in Pediatrics and Neonatology examined preventive effects of larazotide acetate on non-alcoholic fatty liver disease in mouse models
• Colitis: A 2025 study in the Journal of Controlled Release investigated an antibacterial hyaluronic acid hydrogel with sustained larazotide release for colitis treatment

Study Limitations

The available evidence shows a mix of completed, terminated, and ongoing trials, with limited details about sample sizes, specific outcomes, or methodological approaches. The terminated Phase 3 celiac disease trial suggests potential challenges in demonstrating clinical efficacy, though the reasons for termination are not specified in the available evidence.

This summary is based on limited evidence and does not constitute medical advice. Patients should consult healthcare providers for treatment decisions.

Dosing and Administration Protocols

Based on the limited clinical trial evidence available, larazotide acetate has been studied in several dosing regimens, though specific protocol details are not comprehensively reported in the provided literature.

Clinical Trial Context:

• Phase 2 studies have evaluated larazotide acetate for safety and tolerability in celiac disease patients
• A Phase 3 efficacy and safety study for celiac disease symptom relief was terminated
• Current Phase 2 trials are investigating larazotide for long COVID treatment

Reported Administration:
The available evidence indicates larazotide acetate has been administered orally in clinical studies, but specific dosing protocols, frequency of administration, treatment duration, or dose escalation schedules are not detailed in the provided research abstracts.

Preclinical Applications:
Laboratory studies have examined larazotide in various delivery methods, including:

• Sustained-release hydrogel formulations for colitis treatment
• Direct administration in mouse models for conditions including fatty liver disease and intestinal barrier protection

Evidence Limitations:
The current literature provides insufficient detail regarding standardized clinical dosing protocols. Most available information comes from study titles and abstracts rather than complete protocol descriptions.

---

Disclaimer: This information is derived from published research and clinical trial registries and is not intended as personalized medical advice. Any use of larazotide should only be under the direct supervision of a qualified healthcare provider as part of an approved clinical trial or treatment protocol. Dosing and administration decisions must be individualized based on patient-specific factors and current clinical guidelines.

Outcomes

The reported outcomes for larazotide are derived from a limited evidence base consisting primarily of preclinical studies and a small number of clinical trials, with mixed results regarding efficacy.

Clinical Trial Outcomes

Clinical evidence for larazotide is notably limited. A Phase 3 trial evaluating larazotide acetate for celiac disease symptom relief was terminated (NCT03569007), though specific outcome data from this terminated study are not provided in the available evidence. An earlier Phase 2 safety and tolerability study in celiac disease subjects was completed (NCT00362856), but efficacy outcomes are not detailed in the available information.

One ongoing Phase 2 trial is investigating larazotide (AT1001) for long COVID treatment (NCT05747534), but results are not yet available.

Preclinical and Mechanistic Outcomes

Laboratory studies suggest several potential therapeutic mechanisms:

Intestinal Barrier Protection: Studies report that larazotide acetate protects intestinal mucosal barriers from anoxia/reoxygenation injury through various cellular mechanisms, though specific biomarker changes or quantitative measures are not detailed in the available evidence.

Anti-inflammatory Effects: Research indicates larazotide may have preventive effects on non-alcoholic fatty liver disease (NAFLD) in mouse models and potential benefits in colitis when delivered via sustained-release hydrogel formulations.

Post-Viral Recovery: One study reported "viral spike antigen clearance and augmented recovery" in children with post-COVID multisystem inflammatory syndrome treated with larazotide, suggesting potential immunomodulatory effects.

Evidence Limitations

The strength of evidence for larazotide's clinical efficacy remains weak to moderate. The termination of the Phase 3 celiac disease trial raises questions about the compound's therapeutic benefit in its primary indication. Most reported outcomes come from preclinical studies or case reports rather than controlled clinical trials, limiting the ability to draw definitive conclusions about clinical effectiveness.

This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for personalized treatment recommendations.